Your pet may be eligible for one or more of our clinical trials, depending on the diagnosis and overall health of your animal. Your oncology veterinarian will discuss all standard treatment options with you. They will also offer you the opportunity to participate in clinical trials if appropriate, or to consult with the clinical trial coordinator to learn more.
The oncology service runs many ongoing clinical trials for multiple different cancer types at any one time. Please view our available oncology clinical trials program to learn more about the studies that are currently enrolling patients.
If you have further questions about any of our clinical trials, Please either login or sign up to submit a consulting form or call or Oncology Clinical Coordinator at (970) 297-4068.
Available Clinical Trials
Online Consulting Form
To learn more about this study, read the article "Vets Study Stem-Cell Therapy for Chronic Hepatitis."
Any standard poodle suspected or confirmed to have chronic hepatitis
If a liver biopsy is planned, the study will cover the cost of the pathologist's analysis, including special stains and quantitative metal levels. Please see the client information sheet for additional details.
Any cat that produces hairballs.
Cats will receive a free checkup and blood work (Texas A+M GI panel). We ask that the owner provides a fresh, wet hairball placed in a plastic ziplock bag and stored in the fridge.
E-mail Dr. Webb
Any cat that has been diagnosed with diabetes.
This study will determine if Superoxide Dismutase (SOD) aids cats with Diabetes. Cats will receive a free checkups and blood work pre- and post-treatment. This is a double-blind study and there is the possibility of your cat receiving placebo; however, it is possible to receive SOD treatment post-study.
Cats that have been diagnosed with chronic and stable kidney disease and have a creatinine (kidney value) between 2.0 and 5 mg/dl and a “picky” appetite are potentially eligible for entry into the study. A current CBC, chemistry, urinalysis, urine culture, thyroid level and blood pressure are required for entry (the CBC, thyroid level and urine culture will be paid for by the study). Exclusion criteria include other uncontrolled systemic illness (diabetes, inflammatory bowel disease, cancer, liver disease), complications of kidney disease such as kidney infection or decompensation, hospitalization and intravenous fluid therapy. Other concurrent therapies such as diet, famotidine, potassium supplementation, and subcutaneous fluids are acceptable as long as no changes are made during the study period.
Cerenia® is a medication that has been used in veterinary medicine as a short-term anti-nausea drug. A recent pharmacokinetic study in cats indicated that longer-term usage appears safe. We believe that this medication will improve the appetite of cats who are “finicky” due to their kidney disease. Maintaining adequate nutrition is an important part of managing chronic diseases. For more information, view the Cerenia® as an Antinausea Therapy consent form.
E-mail Dr. Quimby
Cats that have been diagnosed with chronic stable kidney disease (creatinine 2.0 to 5.0 mg/dL), without evidence of hereditary kidney disease, based on blood work and ultrasound evaluation, are eligible for entry into the study. Eligible cats must have a current lab work panel (CBC, chemistry, urinalysis, urine culture, thyroid level, and blood pressure) and evaluation of the kidneys by ultrasound. If a heart murmur is present, cardiac ultrasound (echocardiogram) is required to rule out significant heart disease. Concurrent diseases such as diabetes, hyperthyroidism, cancer or heart disease would also be reasons for exclusion from the study.
We have previously performed a pilot study in cats where stem cells were injected intravenously. In this study no cat suffered any ill effect from the treatment and a few cats had mildly improved creatinine and Glomerular Filtration Rate (a measure of kidney function). The purpose of this study is to further explore intravenous stem cell therapy for chronic renal failure in cats in a placebo controlled study. For more information, view the Intravenous Allogeneic Adipose-derived Mesenchymal Stem Cell client consent form.
You have been offered to participate in this study if your pet is suspected of having pyelonephritis, has a simple urinary tract infection, has kidney disease, or is healthy. We need animals in all categories to demonstrate that the blood culture bottles are not only better than standard culture methods, but that they are at least as good.
We are testing a potentially more sensitive way to culture urine so that we can detect infections that do not appear on regular cultures. We will place a small sample of urine in a special bottle normally used to culture bacteria in the bloodstream where there are very few numbers of organisms. These are called blood culture bottles. We are hoping that we can detect more cases of pyelonephritis with this technique. For more information, view the Urine Culture Techniques Study client consent form.
All dogs must be confirmed diabetics based on previous history and blood work (documented glucosuria and blood glucose ≥200mg/dl) and have received insulin therapy for diabetes mellitus for at least two months prior to entering the study. Exclusion criteria include brachycephalic breed (pugs, bulldogs, boxers, etc.), significant systemic disease other than diabetes mellitus, pregnant or lactating, Schirmer tear test less than 5 mm wetting per minute, current treatment with topical ophthalmic medication, any current ocular disease requiring treatment.
Our intent is to demonstrate the effectiveness of topically applied naltrexone in increasing the corneal sensitivity, tear production and tear film break up time in diabetic dogs. If this response can be documented, topical naltrexone could be used to improve the quality of vision and decrease suffering due to corneal disease in diabetic dogs.
Email Dr. Trevor Arnold at firstname.lastname@example.org.
Horses that suffer a rattlesnake bite.
The purpose of this study is to determine whether an equine plasma product (MG Biologics®) is effective at reducing the level of snake venom in the blood of a horse that has been bitten by a rattler. Enrolled horses will receive a 100 mL plasma product, saving $250.00 per dose.
All enrolled horses will receive 100 mL RLTLR equine plasma and will have a temporary catheter placement. 4 mL of blood will be obtained prior to administration of plasma, and 4 mL of blood will be obtained 1 hour after plasma. Lastly, 4 mL of blood will be obtained 24 hours after plasma administration. Blood will be analyzed for snake venom concentrations.
Please email Jenifer.Gold@colostate.edu or Diana.Hassel@colostate.edu.
Adult horses (>1 year old) with surgical disease of the gastrointestinal tract or diarrhea.
The purpose of this study is to characterize the efficacy of phenylmethimazole, a novel and potent anti-inflammatory agent, in reducing signs of endotoxemia and inflammation (high heart rate, pain, reddened mucous membranes, fever) in horses with severe colic or colitis (diarrhea).
Call Dr. Diana Hassel at (970) 297-4271
Apply to CSU |
Contact Us |
Equal Opportunity |
For feedback regarding this site, contact Webmaster at email@example.com.
© Copyright 2013 by College of Veterinary Medicine & Biomedical Sciences
Colorado State University. All Rights Reserved.